Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process.
Adult
Aged
Atrophy
/ diagnostic imaging
Biomarkers
Brain
/ diagnostic imaging
Diagnosis, Differential
Disease Progression
Female
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging
Male
Middle Aged
Neurodegenerative Diseases
/ diagnostic imaging
Neuroimaging
Phenotype
Prion Diseases
/ diagnostic imaging
Severity of Illness Index
Young Adult
Biomarkers
Diagnosis
Gaussian process
Inherited Creutzfeldt–Jakob disease
Prion diseases
Sporadic Creutzfeldt–Jakob disease
Subjects’ stratification
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
04
2019
revised:
25
09
2019
accepted:
21
10
2019
pubmed:
18
11
2019
medline:
23
9
2020
entrez:
18
11
2019
Statut:
ppublish
Résumé
Prion diseases are a group of rare neurodegenerative conditions characterised by a high rate of progression and highly heterogeneous phenotypes. Whilst the most common form of prion disease occurs sporadically (sporadic Creutzfeldt-Jakob disease, sCJD), other forms are caused by prion protein gene mutations, or exposure to prions in the diet or by medical procedures, such us surgeries. To date, there are no accurate quantitative imaging biomarkers that can be used to predict the future clinical diagnosis of a healthy subject, or to quantify the progression of symptoms over time. Besides, CJD is commonly mistaken for other forms of dementia. Due to the heterogeneity of phenotypes and the lack of a consistent geometrical pattern of disease progression, the approaches used to study other types of neurodegenerative diseases are not satisfactory to capture the progression of human form of prion disease. In this paper, using a tailored framework, we aim to classify and stratify patients with prion disease, according to the severity of their illness. The framework is initialised with the extraction of subject-specific imaging biomarkers. The extracted biomakers are then combined with genetic and demographic information within a Gaussian Process classifier, used to calculate the probability of a subject to be diagnosed with prion disease in the next year. We evaluate the effectiveness of the proposed method in a cohort of patients with inherited and sporadic forms of prion disease. The model has shown to be effective in the prediction of both inherited CJD (92% of accuracy) and sporadic CJD (95% of accuracy). However the model has shown to be less effective when used to stratify the different stages of the disease, in which the average accuracy is 85%, whilst the recall is 59%. Finally, our framework was extended as a differential diagnosis tool to identify both forms of CJD among another neurodegenerative disease. In summary we have developed a novel method for prion disease diagnosis and prediction of clinical onset using multiple sources of features, which may have use in other disorders with heterogeneous imaging features.
Identifiants
pubmed: 31734530
pii: S2213-1582(19)30398-5
doi: 10.1016/j.nicl.2019.102051
pmc: PMC6978211
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102051Subventions
Organisme : Medical Research Council
ID : MC_U123160651
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00024/9
Pays : United Kingdom
Organisme : EPA
ID : EP-W-17-011
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00024/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U123160657
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400713
Pays : United Kingdom
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Lancet Neurol. 2005 Oct;4(10):635-42
pubmed: 16168932
AJNR Am J Neuroradiol. 2006 Aug;27(7):1459-62
pubmed: 16908558
Annu Rev Neurosci. 2001;24:519-50
pubmed: 11283320
Clin Radiol. 2001 Sep;56(9):726-39
pubmed: 11585394
IEEE Trans Med Imaging. 2015 Oct;34(10):2079-102
pubmed: 25850086
Clin Anat. 2014 Sep;27(6):821-32
pubmed: 24740900
Neurobiol Aging. 2015 Jan;36 Suppl 1:S42-52
pubmed: 25311276
Eur J Hum Genet. 2006 Mar;14(3):273-81
pubmed: 16391566
Neuroimage. 2011 Jun 1;56(3):1386-97
pubmed: 21316470
IEEE Trans Med Imaging. 2015 Sep;34(9):1976-88
pubmed: 25879909
Brain. 2010 Oct;133(10):3058-68
pubmed: 20881162
Trends Mol Med. 2011 Jan;17(1):14-24
pubmed: 20889378
Brain. 2004 Oct;127(Pt 10):2348-59
pubmed: 15361416
Neuroimage. 2019 Apr 15;190:56-68
pubmed: 29079521
Arch Neurol. 2000 Dec;57(12):1751-7
pubmed: 11115241
J Magn Reson Imaging. 2001 Apr;13(4):534-46
pubmed: 11276097
AJNR Am J Neuroradiol. 2002 Aug;23(7):1164-72
pubmed: 12169476
Neuroimage Clin. 2016 Nov 02;13:89-96
pubmed: 27942451
Neuroreport. 1999 Nov 26;10(17):3471-7
pubmed: 10619628
Radiographics. 2017 Jan-Feb;37(1):234-257
pubmed: 28076012
Neurosurg Focus. 2015 Nov;39(5):E2
pubmed: 26646926
J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):109-14
pubmed: 21849340
Neurology. 2004 Aug 10;63(3):443-9
pubmed: 15304574
Brain. 2010 Oct;133(10):3030-42
pubmed: 20823086
Brain. 2013 Apr;136(Pt 4):1116-27
pubmed: 23550114
J Neuroimaging. 2015 Jan-Feb;25(1):2-13
pubmed: 24593302
Lancet. 2000 Apr 22;355(9213):1412-8
pubmed: 10791525
J Med Imaging (Bellingham). 2014 Jul;1(2):024003
pubmed: 26158035
AJNR Am J Neuroradiol. 2010 Mar;31(3):521-6
pubmed: 20007724
Neurology. 2011 Nov 1;77(18):1674-83
pubmed: 22013183
APMIS. 2002 Jan;110(1):88-98
pubmed: 12064260
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1551-62
pubmed: 15956529
Neuroinformatics. 2016 Jul;14(3):319-37
pubmed: 26972806